{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:20:33Z","timestamp":1760908833406},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1097\/mjt.0b013e318274df35","type":"journal-article","created":{"date-parts":[[2013,5,15]],"date-time":"2013-05-15T16:49:22Z","timestamp":1368636562000},"page":"e169-e170","source":"Crossref","is-referenced-by-count":4,"title":["Cardiovascular Toxicity and Sorafenib"],"prefix":"10.1097","volume":"21","author":[{"given":"Javier","family":"Garc\u00eda-Lled\u00f3","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc\u00eda","family":"Cortejoso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Tenorio N\u00fa\u00f1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1lvaro","family":"Gim\u00e9nez-Manzorro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Matilla-Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Salcedo-Plaza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Sanjurjo-S\u00e1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-29-20210202","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"R2-29-20210202","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1470-2045(08)70003-2","article-title":". Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis.","volume":"9","author":"Wu","year":"2008","journal-title":"Lancet Oncol"},{"key":"R4-29-20210202","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1200\/JCO.2005.04.5740","article-title":"Angiogenesis inhibitors and hypertension: an emerging issue.","volume":"24","author":"Sica","year":"2006","journal-title":"J Clin Oncol"},{"key":"R5-29-20210202","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1161\/CIRCULATIONAHA.108.776831","article-title":"Mechanisms of cardiomyopathy associated with tyrosine kinase inhibitor cancer therapeutics.","volume":"118","author":"Chen","year":"2008","journal-title":"Circulation"},{"key":"R6-29-20210202","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1172\/JCI39434","article-title":". Cardiomyocyte PDGFR- signaling is an essential component of the mouse cardiac response to load-induced stress.","volume":"120","author":"Chintalgattu","year":"2010","journal-title":"J Clin Invest"},{"key":"R7-29-20210202","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.clcc.2011.03.021","article-title":"An algorithm for the management of hypertension in the setting of vascular endothelial growth factor signaling inhibition.","volume":"10","author":"Copur","year":"2011","journal-title":"Clin Colorectal Cancer"},{"key":"R8-29-20210202","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/annonc\/mdn713","article-title":". Management of hypertension in angiogenesis inhibitor-treated patients.","volume":"20","author":"Izzedine","year":"2009","journal-title":"Ann Oncol"},{"key":"R9-29-20210202","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/annonc\/mdp468","article-title":". Acute aortic dissection during sorafenib-containing therapy.","volume":"21","author":"Serrano","year":"2010","journal-title":"Ann Oncol"},{"key":"R10-29-20210202","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1684\/bdc.2010.1068","article-title":". Angiogenesis inhibition: review of the activity of sorafenib, sunitinib and bevacizumab.","volume":"97","author":"Barrascout","year":"2010","journal-title":"Bull Cancer"}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MJT.0b013e318274df35","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:37:32Z","timestamp":1620963452000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045391-201409000-00029"}},"subtitle":["A Case Report"],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":9,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/mjt.0b013e318274df35","relation":{},"ISSN":["1075-2765"],"issn-type":[{"value":"1075-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]}}}